Key Takeaways
- Koselugo showed a benefit in adult patients with the rare condition neurofibromatosis type 1 (NF1) in a Phase III trial.
- The data position AstraZeneca and Merck to expand the MEK inhibitor into a larger patient population. The drug is approved for pediatric NF1 patients, but there are no treatments for adults.
- Koselugo generated $366m in sales during the first nine months of 2024, growing 49% from last year.
AstraZeneca and Merck & Co
Koselugo was approved by the US Food and Drug Administration in 2020 and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?